Q3 EPS Estimates for Haemonetics Increased by Zacks Research

Key Points

• Zacks Research raised its Q3 2027 EPS estimate for Haemonetics to $1.42 (from $1.41) and forecasts Q4 2027 EPS of $1.35, with a consensus full-year estimate of $4.55.
• Haemonetics last reported quarterly results on Feb. 5, beating EPS estimates ($1.31 vs. $1.27) and delivering $338.97M in revenue, though revenue was down 2.7% year-over-year and the company guides FY2026 EPS to $4.90–$5.00.
• Analyst sentiment is generally positive—MarketBeat shows an average rating of "Moderate Buy" and an average price target of $83.89, versus a recent share price near $55.85.

Haemonetics Corporation (NYSE:HAE - Free Report) - Equities research analysts at Zacks Research upped their Q3 2027 earnings per share estimates for shares of Haemonetics in a research report issued on Tuesday, March 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.42 for the quarter, up from their prior estimate of $1.41. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q4 2027 earnings at $1.35 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

A number of other brokerages also recently weighed in on HAE. Citigroup cut their price target on shares of Haemonetics from $75.00 to $70.00 and set a "neutral" rating for the company in a report on Wednesday, March 11th. Needham & Company LLC cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Monday, December 15th. Weiss Ratings reiterated a "hold (c)" rating on shares of Haemonetics in a report on Monday, December 29th. JPMorgan Chase & Co. increased their target price on shares of Haemonetics from $62.00 to $74.00 and gave the company a "neutral" rating in a research note on Friday, December 12th. Finally, Robert W. Baird set a $81.00 target price on shares of Haemonetics in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $83.89.

Haemonetics Price Performance

NYSE:HAE opened at $55.85 on Thursday. The business's 50-day moving average price is $63.00 and its 200 day moving average price is $64.96. The firm has a market cap of $2.60 billion, a P/E ratio of 15.38, a PEG ratio of 1.18 and a beta of 0.28. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in Haemonetics by 372.8% during the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier's stock valued at $102,814,000 after buying an additional 1,678,630 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier's stock worth $110,615,000 after acquiring an additional 1,254,035 shares in the last quarter. Millennium Management LLC increased its position in shares of Haemonetics by 4,296.3% in the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier's stock worth $37,685,000 after acquiring an additional 755,592 shares in the last quarter. North Peak Capital Management LLC raised its holdings in shares of Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier's stock valued at $88,405,000 after acquiring an additional 740,626 shares during the period. Finally, Norges Bank acquired a new stake in shares of Haemonetics during the second quarter valued at approximately $36,822,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.